Corcept Therapeutics Incorporated

Financials

Mittelzufluss aus laufender Geschäftstätigkeit 59.83 M5.13 M43.94 M54.48 M38.45 M 142 M Mittelzufluss aus Investitionstätigkeit -64.36 M-3.17 M70.13 M14.64 M-11.84 M 69.76 M Zahlungsströme aus der Finanzierungstätigkeit -4.56 M-39.8 M-102.93 M-46.41 M-31.22 M -220.37 M Freier Cashflow 59.71 M5.02 M43.88 M54.48 M38.4 M 141.78 M

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

CORT

Financials

Corcept Therapeutics Incorporated

Nachrichten

Corcept: Lifyorli senkt Sterberisiko bei Eierstockkrebs um 35 %

Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?

Corcept Therapeutics: Entwicklungsvorstand Guyer verkauft Aktien im Wert von 819.000 $

Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade) (NASDAQ:CORT)

Catalyst (CPRX) Down 2.5% Since Last Earnings Report: Can It Rebound?

CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer

Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report?

Wolfe Research stuft Corcept Therapeutics nach FDA-Zulassung hoch

FDA erteilt Zulassung für Corcepts Krebsmedikament Lifyorli; Aktie steigt um 21 %

Corcept Therapeutics: Aktie schießt nach FDA-Zulassung für Krebsmedikament in die Höhe

Why Corcept's Ovarian Cancer 'Hail Mary' Might Actually Land (NASDAQ:CORT)

Insiderkauf treibt Aktie von Corcept Therapeutics an